Unicycive Therapeutics, Inc.
NASDAQ:UNCY
0.43 (USD) • At close October 21, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Unicycive Therapeutics, Inc. |
Symbool | UNCY |
Munteenheid | USD |
Prijs | 0.435 |
Beurswaarde | 41,016,640 |
Dividendpercentage | 0% |
52-weken bereik | 0.202 - 1.818 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Shalabh K. Gupta M.D., MPA |
Website | https://www.unicycive.com |
An error occurred while fetching data.
Over Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)